Takeda Pharmaceutical Co Ltd ADR (TAK) Stock Forecast
Alert
Its only available to paid users.
USD 18.00
(+35.03%)
Based on the Takeda Pharmaceutical Co Ltd ADR stock forecast from 1 analysts, the average analyst target price for Takeda Pharmaceutical Co Ltd ADR is USD 18.00 over the next 12 months. Takeda Pharmaceutical Co Ltd ADR’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Takeda Pharmaceutical Co Ltd ADR is Slightly Bullish , which is based on 9 positive signals and 4 negative signals. At the last closing, Takeda Pharmaceutical Co Ltd ADR’s stock price was USD 13.33. Takeda Pharmaceutical Co Ltd ADR’s stock price has changed by -1.77% over the past week, -5.80% over the past month and -4.79% over the last year.
No recent analyst target price found for Takeda Pharmaceutical Co Ltd ADR
No recent average analyst rating found for Takeda Pharmaceutical Co Ltd ADR
Company Overview Takeda Pharmaceutical Co Ltd ADR
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan. Read Less
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapi...Read More
Frequently Asked Questions About Takeda Pharmaceutical Co Ltd ADR (TAK) Stock
Based on ratings from 1 analysts Takeda Pharmaceutical Co Ltd ADR's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 2 buy, sell and hold ratings.
TAK stock's dividend yield is 4.24%.
Our analysis grades TAK stock's dividend yield at A+. This means that TAK stock's dividend yield is above 100% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NYE exchange.
Based on this TAK may be a good dividend stock for its sector.
Based on targets from 1 analysts, the average taret price for TAK is USD 18.00 over the next 12 months. The maximum analyst target price is USD 20 while the minimum anlayst target price is USD 16.
TAK stock's Price/Earning ratio is 23.10.
Our analysis grades TAK stock's Price / Earning ratio at C+. This means that TAK stock's Price/Earning ratio is above 22% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NYE exchange.
Based on this TAK may be undervalued for its sector.
The last closing price of TAK's stock was USD 13.33.
The most recent market capitalization for TAK is USD 45.03B.
Based on targets from 1 analysts, the average taret price for TAK is projected at USD 18.00 over the next 12 months.
This means that TAK's stock price may go up by +35.03% over the next 12 months.
We can't find any ETFs which contains Takeda Pharmaceutical Co Ltd ADR's stock.
As per our most recent records Takeda Pharmaceutical Co Ltd ADR has 49,281 Employees.
Takeda Pharmaceutical Co Ltd ADR's registered address is 1-1, Nihonbashi-Honcho 2-chome, Tokyo, Japan, 103-8668.
You can get more information about it from Takeda Pharmaceutical Co Ltd ADR's website at https://www.takeda.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced on cashflow basis
The stock is trading low compared to its peers on a price to cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
Underpriced compared to earnings
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Superior Dividend Growth
This stock has shown top quartile dividend growth in the previous 5 years compared to its sector
What not to like
Poor return on assets
The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Below median total returns
The company has under performed its peers on annual average total returns in the past 5 years.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Frequently Asked Questions About Takeda Pharmaceutical Co Ltd ADR (TAK) Stock
Based on ratings from 1 analysts Takeda Pharmaceutical Co Ltd ADR's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 2 buy, sell and hold ratings.
TAK stock's dividend yield is 4.24%.
Our analysis grades TAK stock's dividend yield at A+. This means that TAK stock's dividend yield is above 100% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NYE exchange.
Based on this TAK may be a good dividend stock for its sector.
Based on targets from 1 analysts, the average taret price for TAK is USD 18.00 over the next 12 months. The maximum analyst target price is USD 20 while the minimum anlayst target price is USD 16.
TAK stock's Price/Earning ratio is 23.10.
Our analysis grades TAK stock's Price / Earning ratio at C+. This means that TAK stock's Price/Earning ratio is above 22% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NYE exchange.
Based on this TAK may be undervalued for its sector.
The last closing price of TAK's stock was USD 13.33.
The most recent market capitalization for TAK is USD 45.03B.
Based on targets from 1 analysts, the average taret price for TAK is projected at USD 18.00 over the next 12 months.
This means that TAK's stock price may go up by +35.03% over the next 12 months.
We can't find any ETFs which contains Takeda Pharmaceutical Co Ltd ADR's stock.
As per our most recent records Takeda Pharmaceutical Co Ltd ADR has 49,281 Employees.
Takeda Pharmaceutical Co Ltd ADR's registered address is 1-1, Nihonbashi-Honcho 2-chome, Tokyo, Japan, 103-8668.
You can get more information about it from Takeda Pharmaceutical Co Ltd ADR's website at https://www.takeda.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for TAK !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
